Anderson, K. C. (2017). Should minimal residual disease negativity be the end point of myeloma therapy? Blood Adv.
シカゴスタイル引用形Anderson, Kenneth C. "Should Minimal Residual Disease Negativity Be the End Point of Myeloma Therapy?" Blood Adv 2017.
MLA引用形式Anderson, Kenneth C. "Should Minimal Residual Disease Negativity Be the End Point of Myeloma Therapy?" Blood Adv 2017.
警告: この引用は必ずしも正確ではありません.